Cidara Thera (CDTX)

$221.38 +0.06 (0.03%)
Market Cap 6.95B
Revenue (ttm) 1.28M
Net Income (ttm) -169.83M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -13,267.97%
Debt to Equity Ratio 0.00
Volume 2,691,000
Avg Vol 1,496,326
Day's Range N/A - N/A
Shares Out 31.44M
Stochastic %K 96%
Beta 1.52
Analysts Sell
Price Target $207.30

Company Profile

Cidara Therapeutics, Inc. operates as a biotechnology company that focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enab...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 752 6170
Address:
6310 Nancy Ridge Drive, Suite 101, San Diego, United States
resurrect_momo21
resurrect_momo21 Mar. 10 at 6:12 PM
$ANTX $COCP $CDTX plenty of cash to fund existing trial and then some -plus outstanding detached warrants from insider private placement & last offering $15-17 mil cash more importantly Barda military funds will moonshot this
0 · Reply
resurrect_momo21
resurrect_momo21 Mar. 10 at 12:40 PM
$ANTX $COCP I will explain cocrystal pharma but keep it short since angry bashers will emply their savings and buy hand over fist - its not a phase 1 it is a 1b/2 in a $60 b plus space no other drugs exist on the planet or even close - take a look at mgmt - yeah the clinical bio had some set backs but need just one monster drug look at $CDTX 25m to $9 b antiviral vaccine with tons of compettion - once show effectiantly worth billions - plus gov funds will hit anytime
1 · Reply
SellasgpsCurativeBAT9
SellasgpsCurativeBAT9 Mar. 5 at 1:58 PM
$CDTX $SLS Sellas Shorts only 100,000 left to Borrow 👇 at double digit borrow rate. Shorts already used up 50,000 in Pre Market. We will keep on marching towards first base of $7.06 before first trading halt. Halt due to overwhelming GPS efficacy = $60.00+ BO= $120.00+ Bidding war = $240.00+ 🙏❤️‍🩹☝️
0 · Reply
SellasgpsCurativeBAT9
SellasgpsCurativeBAT9 Mar. 5 at 1:48 PM
$CDTX $SLS I had a small position in CDTX before BO. I combed through all the SEC filings post Cidara BO. CDTX BOD was going back and forth for about 60 days with 5 different bidders for not FDA approved flu vaccine. Merck ended up as highest bidder with $9 Billion BO= $222.00 per share. ✌️🙏❤️‍🩹☝️
0 · Reply
samsha1
samsha1 Feb. 26 at 2:34 PM
$CDTX $SLS both CEO's have unwavering conviction.
0 · Reply
samsha1
samsha1 Feb. 26 at 2:30 PM
$SLS $CDTX is the blueprint run from $20-$200 plus buyout based on a phase 2 flu drug. SLS will run from $4 to $150 based on an HR.<.4- manifesting.
0 · Reply
WickObserver
WickObserver Feb. 18 at 10:25 AM
$CDTX Biotech with delayed catalysts and funding risk.
0 · Reply
Pissed_of_retards2
Pissed_of_retards2 Feb. 11 at 8:08 PM
$NVAX $CDTX $MRK
0 · Reply
Pissed_of_retards2
Pissed_of_retards2 Feb. 11 at 4:48 PM
$NVAX wtf $CDTX $MRK
0 · Reply
RealAvidTrader
RealAvidTrader Feb. 10 at 3:03 AM
$CDTX Lets Not Forget $45M Market Cap To Getting Acquired For $9B… Will Be Hard To Top This One Folks
2 · Reply
Latest News on CDTX
Cidara Therapeutics Reaches Target Enrollment of Phase 3 ANCHOR Trial Evaluating CD388 for Prevention of Seasonal Influenza in High-Risk Populations

Nov 24, 2025, 8:00 AM EST - 4 months ago

Cidara Therapeutics Reaches Target Enrollment of Phase 3 ANCHOR Trial Evaluating CD388 for Prevention of Seasonal Influenza in High-Risk Populations

Big Pharma Has Spent Nearly $150 Billion On M&A (So Far) In 2025

Nov 19, 2025, 1:05 PM EST - 4 months ago

Big Pharma Has Spent Nearly $150 Billion On M&A (So Far) In 2025

MRK

Merck expects over $5 billion commercial opportunity from Cidara's flu drug

Nov 17, 2025, 8:34 AM EST - 4 months ago

Merck expects over $5 billion commercial opportunity from Cidara's flu drug

MRK

Top 2 Health Care Stocks That May Fall Off A Cliff This Month

Nov 17, 2025, 8:15 AM EST - 4 months ago

Top 2 Health Care Stocks That May Fall Off A Cliff This Month

AVDL

Cidara Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Cidara Therapeutics, Inc. - CDTX

Nov 16, 2025, 6:49 PM EST - 4 months ago

Cidara Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Cidara Therapeutics, Inc. - CDTX

MRK

If M&A continues at this pace you want to be long Biotech into next year, says Mizuho's Jared Holz

Nov 14, 2025, 6:17 PM EST - 4 months ago

If M&A continues at this pace you want to be long Biotech into next year, says Mizuho's Jared Holz

IBB MRK XBI XLV

This Biotech's Stock Price More Than Doubled on Friday. Here's Why.

Nov 14, 2025, 4:25 PM EST - 4 months ago

This Biotech's Stock Price More Than Doubled on Friday. Here's Why.

This is why Merck is buying Cidara Therapeutics for $9.2 billion, and why Wall Street is happy

Nov 14, 2025, 11:20 AM EST - 4 months ago

This is why Merck is buying Cidara Therapeutics for $9.2 billion, and why Wall Street is happy

MRK

NVDA Price Target Hikes, STUB Shows No Guidance, MRK Buying CDTX

Nov 14, 2025, 10:00 AM EST - 4 months ago

NVDA Price Target Hikes, STUB Shows No Guidance, MRK Buying CDTX

MRK NVDA STUB

Merck to buy Cidara Therapeutics for $9.2 billion as Keytruda patent cliff approaches

Nov 14, 2025, 8:30 AM EST - 4 months ago

Merck to buy Cidara Therapeutics for $9.2 billion as Keytruda patent cliff approaches

MRK

Merck to Buy Cidara Therapeutics in $9.2 Billion Deal

Nov 14, 2025, 7:16 AM EST - 4 months ago

Merck to Buy Cidara Therapeutics in $9.2 Billion Deal

MRK

Merck bets on flu prevention with about $9.2 billion deal for Cidara Therapeutics

Nov 14, 2025, 6:51 AM EST - 4 months ago

Merck bets on flu prevention with about $9.2 billion deal for Cidara Therapeutics

MRK

Merck to Acquire Cidara Therapeutics, Inc., Diversifying Its Portfolio to Include Late-Phase Antiviral Agent

Nov 14, 2025, 6:45 AM EST - 4 months ago

Merck to Acquire Cidara Therapeutics, Inc., Diversifying Its Portfolio to Include Late-Phase Antiviral Agent

MRK

Wall Street Breakfast Podcast: Merck Talks Send Cidara Soaring

Nov 14, 2025, 6:09 AM EST - 4 months ago

Wall Street Breakfast Podcast: Merck Talks Send Cidara Soaring

DASH MRK

Merck nearing deal for Cidara, FT reports

Nov 13, 2025, 6:53 PM EST - 4 months ago

Merck nearing deal for Cidara, FT reports

MRK

Cidara Therapeutics, Inc. (CDTX) Q3 2025 Earnings Call Transcript

Nov 7, 2025, 2:56 PM EST - 4 months ago

Cidara Therapeutics, Inc. (CDTX) Q3 2025 Earnings Call Transcript

Cidara Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results

Nov 6, 2025, 4:07 PM EST - 4 months ago

Cidara Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results

Cidara Therapeutics to Participate in November Investor Conferences

Oct 28, 2025, 8:00 AM EDT - 5 months ago

Cidara Therapeutics to Participate in November Investor Conferences

Cidara Therapeutics to Report Third Quarter 2025 Financial Results and Host Quarterly Conference Call on November 6, 2025

Oct 23, 2025, 4:05 PM EDT - 5 months ago

Cidara Therapeutics to Report Third Quarter 2025 Financial Results and Host Quarterly Conference Call on November 6, 2025

Cidara Therapeutics Announces Late-Breaking Presentation on CD388 at 10ᵗʰ ESWI Influenza Conference 2025

Oct 23, 2025, 8:00 AM EDT - 5 months ago

Cidara Therapeutics Announces Late-Breaking Presentation on CD388 at 10ᵗʰ ESWI Influenza Conference 2025

Cidara Therapeutics: A Potential Blockbuster In Flu Prevention

Oct 21, 2025, 12:52 PM EDT - 5 months ago

Cidara Therapeutics: A Potential Blockbuster In Flu Prevention

Cidara Therapeutics Announces Late-Breaking Phase 2b Data Presentation on CD388 at ID Week 2025

Oct 21, 2025, 8:00 AM EDT - 5 months ago

Cidara Therapeutics Announces Late-Breaking Phase 2b Data Presentation on CD388 at ID Week 2025

Cidara Therapeutics to Present Late-Breaking Clinical Phase 2 Data on CD388 at ID Week 2025

Oct 13, 2025, 8:00 AM EDT - 5 months ago

Cidara Therapeutics to Present Late-Breaking Clinical Phase 2 Data on CD388 at ID Week 2025

Cidara Therapeutics to Present at 10th ESWI Influenza Conference 2025

Oct 10, 2025, 8:00 AM EDT - 5 months ago

Cidara Therapeutics to Present at 10th ESWI Influenza Conference 2025

Cidara Therapeutics Receives U.S. FDA Breakthrough Therapy Designation for CD388 in Seasonal Influenza Prevention

Oct 9, 2025, 8:00 AM EDT - 5 months ago

Cidara Therapeutics Receives U.S. FDA Breakthrough Therapy Designation for CD388 in Seasonal Influenza Prevention

Cidara Therapeutics Announces BARDA Award to Support Expanded Manufacturing and Clinical Development of CD388, its Non-Vaccine Influenza Preventative Therapeutic

Oct 2, 2025, 4:01 PM EDT - 5 months ago

Cidara Therapeutics Announces BARDA Award to Support Expanded Manufacturing and Clinical Development of CD388, its Non-Vaccine Influenza Preventative Therapeutic

Cidara Therapeutics Announces First Participants Dosed in Phase 3 ANCHOR Trial Evaluating CD388 for the Prevention of Seasonal Influenza in High-Risk Populations

Sep 25, 2025, 4:01 PM EDT - 6 months ago

Cidara Therapeutics Announces First Participants Dosed in Phase 3 ANCHOR Trial Evaluating CD388 for the Prevention of Seasonal Influenza in High-Risk Populations

Cidara Therapeutics Announces Expanded and Accelerated Phase 3 Plan for CD388, a Non-Vaccine Preventative of Seasonal Influenza

Sep 24, 2025, 7:00 AM EDT - 6 months ago

Cidara Therapeutics Announces Expanded and Accelerated Phase 3 Plan for CD388, a Non-Vaccine Preventative of Seasonal Influenza

Cidara Therapeutics Presents Data on CD388 from its Phase 2b NAVIGATE Trial and Preclinical Studies Against H5N1 at ISRV's 8th AVG and 3rd IMRP 2025 Meeting

Sep 17, 2025, 8:00 AM EDT - 6 months ago

Cidara Therapeutics Presents Data on CD388 from its Phase 2b NAVIGATE Trial and Preclinical Studies Against H5N1 at ISRV's 8th AVG and 3rd IMRP 2025 Meeting

Cidara Therapeutics, Inc. (CDTX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 9, 2025, 12:41 PM EDT - 6 months ago

Cidara Therapeutics, Inc. (CDTX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Cidara Therapeutics to Participate in September Investor Conferences

Sep 4, 2025, 8:00 AM EDT - 6 months ago

Cidara Therapeutics to Participate in September Investor Conferences

Cidara Therapeutics to Present Clinical Phase 2b Data and Preclinical H5N1 Data on CD388 at ISRV's 8th AVG and 3rd IMRP 2025 Meeting

Sep 3, 2025, 8:00 AM EDT - 7 months ago

Cidara Therapeutics to Present Clinical Phase 2b Data and Preclinical H5N1 Data on CD388 at ISRV's 8th AVG and 3rd IMRP 2025 Meeting

Cidara Therapeutics: Still Big Catalysts Ahead Following Impressive Ph2b Readout

Aug 15, 2025, 1:07 PM EDT - 7 months ago

Cidara Therapeutics: Still Big Catalysts Ahead Following Impressive Ph2b Readout

Cidara Therapeutics, Inc. (CDTX) Q2 2025 Earnings Call Transcript

Aug 8, 2025, 6:04 PM EDT - 7 months ago

Cidara Therapeutics, Inc. (CDTX) Q2 2025 Earnings Call Transcript

Cidara Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results

Aug 7, 2025, 4:05 PM EDT - 7 months ago

Cidara Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results

Cidara Therapeutics to Report Second Quarter 2025 Financial Results and Host Quarterly Conference Call on August 7, 2025

Jul 24, 2025, 8:00 AM EDT - 8 months ago

Cidara Therapeutics to Report Second Quarter 2025 Financial Results and Host Quarterly Conference Call on August 7, 2025

Segal Trials Contributes to Breakthrough Flu Prevention Study Led by Cidara Therapeutics

Jul 7, 2025, 1:00 PM EDT - 9 months ago

Segal Trials Contributes to Breakthrough Flu Prevention Study Led by Cidara Therapeutics

Cidara Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Jul 1, 2025, 4:59 PM EDT - 9 months ago

Cidara Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Cidara Therapeutics Announces Inclusion in the Russell 2000® and Russell 3000® Indexes

Jun 30, 2025, 8:00 AM EDT - 9 months ago

Cidara Therapeutics Announces Inclusion in the Russell 2000® and Russell 3000® Indexes

Cidara Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

Jun 26, 2025, 5:15 PM EDT - 9 months ago

Cidara Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

Cidara Therapeutics Advances CD388 To Phase 3, Reiterate Buy

Jun 25, 2025, 7:30 AM EDT - 9 months ago

Cidara Therapeutics Advances CD388 To Phase 3, Reiterate Buy

Cidara Announces Pricing of Upsized Public Offering of Common Stock

Jun 24, 2025, 8:00 PM EDT - 9 months ago

Cidara Announces Pricing of Upsized Public Offering of Common Stock

Cidara Announces Proposed Public Offering of Common Stock

Jun 23, 2025, 4:15 PM EDT - 9 months ago

Cidara Announces Proposed Public Offering of Common Stock

Why Is Cidara Therapeutics Stock Trading Higher On Monday?

Jun 23, 2025, 11:00 AM EDT - 9 months ago

Why Is Cidara Therapeutics Stock Trading Higher On Monday?

Cidara Therapeutics Announces Positive Topline Results from its Phase 2b NAVIGATE Trial Evaluating CD388, a Non-Vaccine Preventative of Seasonal Influenza

Jun 23, 2025, 7:00 AM EDT - 9 months ago

Cidara Therapeutics Announces Positive Topline Results from its Phase 2b NAVIGATE Trial Evaluating CD388, a Non-Vaccine Preventative of Seasonal Influenza

Cidara Therapeutics: All Stars Aligning In Favor Of CD388

May 25, 2025, 9:26 PM EDT - 10 months ago

Cidara Therapeutics: All Stars Aligning In Favor Of CD388

Cidara Therapeutics to Host Virtual R&D Day to Discuss CD388 as a Potential Universal, Once-Per-Flu Season Preventative of Seasonal and Pandemic Influenza on May 22, 2025

May 15, 2025, 8:00 AM EDT - 10 months ago

Cidara Therapeutics to Host Virtual R&D Day to Discuss CD388 as a Potential Universal, Once-Per-Flu Season Preventative of Seasonal and Pandemic Influenza on May 22, 2025

Cidara Therapeutics to Participate in Two Upcoming Investor Conferences

May 13, 2025, 8:00 AM EDT - 11 months ago

Cidara Therapeutics to Participate in Two Upcoming Investor Conferences

resurrect_momo21
resurrect_momo21 Mar. 10 at 6:12 PM
$ANTX $COCP $CDTX plenty of cash to fund existing trial and then some -plus outstanding detached warrants from insider private placement & last offering $15-17 mil cash more importantly Barda military funds will moonshot this
0 · Reply
resurrect_momo21
resurrect_momo21 Mar. 10 at 12:40 PM
$ANTX $COCP I will explain cocrystal pharma but keep it short since angry bashers will emply their savings and buy hand over fist - its not a phase 1 it is a 1b/2 in a $60 b plus space no other drugs exist on the planet or even close - take a look at mgmt - yeah the clinical bio had some set backs but need just one monster drug look at $CDTX 25m to $9 b antiviral vaccine with tons of compettion - once show effectiantly worth billions - plus gov funds will hit anytime
1 · Reply
SellasgpsCurativeBAT9
SellasgpsCurativeBAT9 Mar. 5 at 1:58 PM
$CDTX $SLS Sellas Shorts only 100,000 left to Borrow 👇 at double digit borrow rate. Shorts already used up 50,000 in Pre Market. We will keep on marching towards first base of $7.06 before first trading halt. Halt due to overwhelming GPS efficacy = $60.00+ BO= $120.00+ Bidding war = $240.00+ 🙏❤️‍🩹☝️
0 · Reply
SellasgpsCurativeBAT9
SellasgpsCurativeBAT9 Mar. 5 at 1:48 PM
$CDTX $SLS I had a small position in CDTX before BO. I combed through all the SEC filings post Cidara BO. CDTX BOD was going back and forth for about 60 days with 5 different bidders for not FDA approved flu vaccine. Merck ended up as highest bidder with $9 Billion BO= $222.00 per share. ✌️🙏❤️‍🩹☝️
0 · Reply
samsha1
samsha1 Feb. 26 at 2:34 PM
$CDTX $SLS both CEO's have unwavering conviction.
0 · Reply
samsha1
samsha1 Feb. 26 at 2:30 PM
$SLS $CDTX is the blueprint run from $20-$200 plus buyout based on a phase 2 flu drug. SLS will run from $4 to $150 based on an HR.<.4- manifesting.
0 · Reply
WickObserver
WickObserver Feb. 18 at 10:25 AM
$CDTX Biotech with delayed catalysts and funding risk.
0 · Reply
Pissed_of_retards2
Pissed_of_retards2 Feb. 11 at 8:08 PM
$NVAX $CDTX $MRK
0 · Reply
Pissed_of_retards2
Pissed_of_retards2 Feb. 11 at 4:48 PM
$NVAX wtf $CDTX $MRK
0 · Reply
RealAvidTrader
RealAvidTrader Feb. 10 at 3:03 AM
$CDTX Lets Not Forget $45M Market Cap To Getting Acquired For $9B… Will Be Hard To Top This One Folks
2 · Reply
Young_Antarian
Young_Antarian Jan. 29 at 5:41 PM
$IVVD Pemgarda surprise or measles program update could spike share price. Surprised after $CDTX takeover by $MRK nobody has taken a run at them for cheap
1 · Reply
ADSlay
ADSlay Jan. 26 at 7:08 PM
$QNCX Woah! $QNCX team is pretty much $CDTX! Wow! Had no idea. Quince CEO/CMO Thye was Cidara's first CMO! And that's where he met QNCX COO Brendan Hannah, wow! Daammmnn!! For context: CDTX got bot out by Merck for $9.2 billion 🚀 This just dropped: https://youtu.be/Wdyl33epIZs?si=jwprSA0hxnuD95oc
6 · Reply
alexgunning
alexgunning Jan. 23 at 10:06 PM
$IBRX $CDTX I stuck with CDTX to $221.00. Which is now my budget for IBRX. I’ll keep buying these dips..
0 · Reply
Johnmtnb2018
Johnmtnb2018 Jan. 23 at 3:46 PM
$CDTX $SLS Angelos have been silent on the corporate side. No form 4. No update call this year. Yep! This company is about to be sold out and PR will hit next week!
0 · Reply
Johnmtnb2018
Johnmtnb2018 Jan. 23 at 3:32 PM
$CDTX $SLS CDTX had 6 offers in the bidding war. Merck (MRK) successfully completed its acquisition of Cidara Therapeutics (CDTX) in early January 2026 for $221.50 per share in cash, totaling about $9.2 billion. *******************Not FDA approved to strengthen Merck's respiratory portfolio with Cidara's flu antiviral drug, CD388. ! Let’s see how many bidders Sellas has when the deal 10K comes out !
0 · Reply
Coldfusionh2
Coldfusionh2 Jan. 22 at 4:13 PM
$CDTX $SLS Oh yeah. Well I’ve been in biotech for nearly 145 years.
0 · Reply
Johnmtnb2018
Johnmtnb2018 Jan. 22 at 4:06 PM
$SLS $CDTX This is the kind of trading Action before a trading halt. I have been watching M&A in Biotechnology sector for 35 years plus. Same action at CDTX before BO at $220 !
0 · Reply
shopno
shopno Jan. 17 at 2:29 AM
$IOVA idiot Rothbaum probably imagined a TIL-therapy would have a $CDTX like exit, when stock 2x on trial update, and got acquired by MRK for ~500% higher at $9+ billions pre-commmerical. Indeed IOVA went 2x after fda approval. But then incompetent management took all mis-steps to kill 90%+ stock valuations.
1 · Reply
AlphaOfBiotech
AlphaOfBiotech Jan. 15 at 5:08 AM
$FATE is trading at half of its cash of $226M (as of late 2025). You are essentially getting the entire iPSC pipeline, 500+ patents, and a state-of-the-art manufacturing facility for free. What is happening to $CDTX $VTYX $TERN las last year will be repeated here soon! Wish us good luck! Go $FATE !
1 · Reply
Pjdevx
Pjdevx Jan. 14 at 10:01 PM
$CADL If $CDTX is a 9B acquisition CADL is right up there. Willing to wait.
0 · Reply
Hero07
Hero07 Jan. 13 at 7:15 PM
$NUVB Dr. Hung knows the Value in stacking ROA1 patients, and Drug and drug conjugation platform. this will be the next $CDTX buyout, $GILD looking yet!
1 · Reply
Johnmtnb2018
Johnmtnb2018 Jan. 13 at 4:05 PM
$SLS $CDTX Bidding war like CDTX = $200 +
0 · Reply